FLT3 and acute myeloid leukemia: When selection pressure is applied to FLT3 inhibitors, clones with mutations are selected out, but FLT3 wild-type AML subclones with other genetic mutations present before administration increase or acquire new non-FLT3 mutations and develop resistance [50,51].